Inhibrx Biosciences, Inc. (INBX) Research

Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions. Its pipeline features several investigational therapies, notably INBRX-109. This tetravalent therapeutic candidate, which targets death-receptor 5, is undergoing Phase 2 clinical trials for managing conventional chondrosarcoma that is either unresectable or has spread. Another significant asset is INBRX-106, a hexavalent sdAb-based candidate engineered to engage OX4, also in Phase 2 clinical evaluation. This drug aims to treat a broad spectrum of advanced cancers, including metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA), renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was established in 2024 and is headquartered in La Jolla, California.

Market snapshot

Symbol
INBX
Price
$93.05
Day change
-1.22%
Market cap
$1.4B
P/E ratio
-11.14x
52-week range
13.97-155.29
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$325

Recent news

  • Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

    Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc.'s (NYSE:MRK) Keytruda (pembrolizumab) for treating head and neck cancer.

  • Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

    Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.

  • Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

    Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer ​treatment that could be valued at more than $8 billion, people familiar with the matter said.

Peer companies

  • Amylyx Pharmaceuticals, Inc. (AMLX)
  • Atai Beckley Inc. (ATAI)
  • CureVac N.V. (CVAC)
  • Enliven Therapeutics, Inc. (ELVN)
  • Immatics N.V. (IMTX)
  • Nektar Therapeutics (NKTR)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Relay Therapeutics, Inc. (RLAY)

Recent insider activity

  • Vuori Kristiina MD — A-Award (15000 shares) on 2026-06-03
  • Kayyem Jon Faiz — A-Award (15000 shares) on 2026-06-03
  • FORSYTH DOUGLAS — A-Award (15000 shares) on 2026-06-03
  • MANHARD KIMBERLY — A-Award (15000 shares) on 2026-06-03
  • Matly David — A-Award (50000 shares) on 2026-04-24

Open Inhibrx Biosciences, Inc. (INBX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.